Experience with PCR Testing for Enteric Bacteria and Viruses of Emergency Department Patients with Acute Gastroenteritis: Are There Implications for the Early Treatment of Clostridioides difficile Infection?
Abstract
:1. Introduction
2. Results
2.1. BD MAX PCR Testing
2.2. Hygiene Management
2.3. C. difficile
3. Discussion
4. Materials and Methods
4.1. PCR Testing and Microbiology Diagnostic Workflows
4.2. Data Analysis
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Ferrer, J.; Giménez, E.; Carretero, D.; Buesa, J.; Morillas, F.; Granell, R.; Fuenmayor, A.; Navarro, D.; Albert, E. BD MAX enteric bacterial, bacterial plus and virus panels for diagnosis of acute infectious gastroenteritis: A cost-benefit analysis. Microbiol. Spectr. 2022, 10, e0088022. [Google Scholar] [CrossRef] [PubMed]
- Valledor, S.; Valledor, I.; Gil-Rodríguez, M.C.; Seral, C.; Castillo, J. Comparison of several real-time PCR kits versus a culture-dependent algorithm to identify enteropathogens in stool samples. Sci. Rep. 2020, 10, 4301. [Google Scholar] [CrossRef] [PubMed]
- Powell, E.A.; Hata, D.J.; Starolis, M.W. Viral pathogen detection using multiplex gastrointestinal molecular panels: The pros and cons of viral target inclusion. J. Clin. Virol. 2023, 169, 105612. [Google Scholar] [CrossRef] [PubMed]
- Truong, J.; Cointe, A.; Le Roux, E.; Bidet, P.; Michel, M.; Boize, J.; Mariani-Kurkdjian, P.; Caseris, M.; Hobson, C.A.; Desmarest, M.; et al. Clinical impact of a gastrointestinal PCR panel in children with infectious diarrhoea. Arch. Dis. Child. 2022, 107, 601–605. [Google Scholar] [CrossRef] [PubMed]
- Kanwar, N.; Jackson, J.; Bardsley, T.; Pavia, A.; Bourzac, K.M.; Holmberg, K.; Selvarangan, R. Impact of rapid molecular multiplex gastrointestinal pathogen testing in management of children during a Shigella outbreak. J. Clin. Microbiol. 2023, 61, e0165222. [Google Scholar] [CrossRef] [PubMed]
- Carius, B.M.; Liang, S.Y.; Koyfman, A.; Long, B. Clostridioides difficile infection evaluation and management in the emergency department. Am. J. Emerg. Med. 2020, 38, 2203–2208. [Google Scholar] [CrossRef] [PubMed]
- Brendish, N.J.; Beard, K.R.; Malachira, A.K.; Tanner, A.R.; Sanga-Nyirongo, L.; Gwiggner, M.; Cummings, J.R.F.; Moyses, H.E.; Clark, T.W. Clinical impact of syndromic molecular point-of-care testing for gastrointestinal pathogens in adults hospitalised with suspected gastroenteritis (GastroPOC): A pragmatic, open-label, randomised controlled trial. Lancet Infect. Dis. 2023, 23, 945–955. [Google Scholar] [CrossRef] [PubMed]
- DiDiodato, G.; Allen, A.; Bradbury, N.; Brown, J.; Cruise, K.; Jedrzejko, C.; MacDonald, V.; Pigeon, J.; Sturgeon, A.; Yellenik, D. The efficacy of the BioFire FilmArray gastrointestinal panel to reduce hospital costs associated with contact isolation: A pragmatic randomized controlled trial. Cureus 2022, 14, e27931. [Google Scholar] [CrossRef] [PubMed]
- Crobach, M.J.; Planche, T.; Eckert, C.; Barbut, F.; Terveer, E.M.; Dekkers, O.M.; Wilcox, M.H.; Kuijper, E.J. European Society of Clinical Microbiology and Infectious Diseases: Update of the diagnostic guidance document for Clostridium difficile infection. Clin. Microbiol. Infect. 2016, 22, S63–S81. [Google Scholar] [CrossRef] [PubMed]
- McDonald, L.C.; Gerding, D.N.; Johnson, S.; Bakken, J.S.; Carroll, K.C.; Coffin, S.E.; Dubberke, E.R.; Garey, K.W.; Gould, C.V.; Kelly, C.; et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin. Infect. Dis. 2018, 66, e1–e48. [Google Scholar] [CrossRef] [PubMed]
- Dbeibo, L.; Lucky, C.W.; Fadel, W.F.; Sadowski, J.; Beeler, C.; Kelley, K.; Williams, J.; Webb, D.; Kara, A. Two-step algorithm-based Clostridioides difficile testing as a tool for antibiotic stewardship Clin. Microbiol. Infect. 2023, 29, e1–e798. [Google Scholar] [CrossRef]
- Bettger, C.C.; Giancola, S.E.; Cybulski, R.J., Jr.; Okulicz, J.F.; Barsoumian, A.E. Evaluation of a two step testing algorithm to improve diagnostic accuracy and stewardship of Clostridioides difficile infections BMC Res. Notes 2023, 16, 172. [Google Scholar] [CrossRef]
- Hecker, M.T.; Son, A.H.; Zuccaro, P.; Conti, J.; Donskey, C.J. Real-world evaluation of a two-step testing algorithm for Clostridioides difficile infection. Infect. Control. Hosp. Epidemiol. 2023, 44, 1494–1496. [Google Scholar] [CrossRef] [PubMed]
- Lim, V.W.; Tomaru, T.; Chua, B.; Ma, Y.; Yanagihara, K. Budget impact analysis of adopting a one-step nucleic acid amplification testing (NAAT) alone diagnostic pathway for Clostridioides difficile in Japan compared to a two-step algorithm with glutamate dehydrogenase/toxin followed by NAAT. Diagnostics 2023, 13, 1463. [Google Scholar] [CrossRef] [PubMed]
- Shirley, D.A.; Tornel, W.; Warren, C.A.; Moonah, S. Clostridioides difficile infection in children: Recent updates on epidemiology, diagnosis, therapy. Pediatrics 2023, 152, e2023062307. [Google Scholar] [CrossRef] [PubMed]
- Doolan, C.P.; Louie, T.; Lata, C.; Larios, O.E.; Stokes, W.; Kim, J.; Brown, K.; Beck, P.; Deardon, R.; Pillai, D.R. Latent class analysis for the diagnosis of Clostridioides difficile infection. Clin. Infect. Dis. 2021, 73, e2673–e2679. [Google Scholar] [CrossRef] [PubMed]
- Mah, R.; Locher, K.; Steiner, T.S.; Stefanovic, A. Clostridioides difficile PCR Tcdb cycle threshold predicts toxin EIA positivity but not severity of infection. Anaerobe 2023, 82, 102755. [Google Scholar] [CrossRef] [PubMed]
- Covino, M.; Gallo, A.; Pero, E.; Simeoni, B.; Macerola, N.; Murace, C.A.; Ibba, F.; Landi, F.; Franceschi, F.; Montalto, M. Early prognostic stratification of Clostridioides difficile infection in the emergency department: The role of age and comorbidities. J. Pers. Med. 2022, 12, 1573. [Google Scholar] [CrossRef] [PubMed]
- Skjøt-Arkil, H.; Rune Nanthan, K.; Chen, M.; Rosenvinge, F.S. Carrier prevalence of Clostridioides difficile in emergency departments and the association of prior antibiotic consumption: A combined cross-sectional and nested case-control study. J. Antimicrob. Chemother. 2023, 78, 2089–2096. [Google Scholar] [CrossRef] [PubMed]
- van Prehn, J.; Reigadas, E.; Vogelzang, E.H.; Bouza, E.; Hristea, A.; Guery, B.; Krutova, M.; Norén, T.; Allerberger, F.; Guideline Committee of the European Study Group on Clostridioides difficile. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin. Microbiol. Infect. 2021, 27, S1–S21. [Google Scholar] [CrossRef] [PubMed]
Pathogens | Patient Group | ||
---|---|---|---|
Pediatric (<18) | Adults (18–65) | Elderly (>65) | |
Number of positive patients/total number of patients | 15/36 (41.67) | 15/35 (42.85) | 26/62 (41.9) |
No. of positive PCR results | 19 | 16 | 26 |
Campylobacter spp. | 3 | 2 | 5 |
Salmonella spp. | 4 | 1 | 3 |
STEC | 0 | 2 | 0 |
Shigella spp. | 0 | 1 | 0 |
C. difficile | 3 | 3 | 14 |
Norovirus | 5 | 5 | 4 |
Rotavirus | 1 | 1 | 0 |
Astrovirus | 2 | 1 | 0 |
Co-infections | 3 a | 1 b | 0 |
Median Time of Isolation (IQR), h | p-Value | ||
---|---|---|---|
PCR-Negative (n = 50) | PCR-Positive (n = 35) | ||
Hospital length of stay | 156.75 (114.33–261.51) | 143 (112.5–259) | 0.608 |
Single-room isolation | 104 (22.75–156.75) | 139.75 (67–245.5) | 0.039 |
No. | Underlying Disease | Symptoms | Age | Sex | Time to PCR Result (h) | Length of Stay in the ED (h) | Hospitalization | CDI Diagnosis | Start of Antibiotic Treatment after Admission to the ED (h) | Iso-Lation (h) | Hospital Length of Stay (h) | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PCR Ct Value | WBC 1 (Gpt/mL) | Creatinine 1 (mmol/L) | Recurrence (R), First Diagnosis (F), or non Relevant (N) | |||||||||||
1 | Stroke condition | Diarrhea and fever | 74 | f | 4.83 | 11.5 | No 2 | 26.3 | 24.8 | 88 | R | Vancomycin and metronidazole (7.22) | ||
2 | COPD 3, Crohn’s disease, recurrent UTI 4, and CHD 5 | Diarrhea, kidney failure, and metabolic acidosis | 73 | m | 4.25 | 6.77 | Yes | 24.7 | 12.6 | 246 | F | Vancomycin (5.1) and piperacillin– tazobactam (5.75) | 161.75 | 168.5 |
3 | Alzheimer’s disease and recurrent UTI 4 | Diarrhea | 96 | f | 3.68 | 10.17 | Yes | 25.1 | 22.4 | 113 | F | None | 259 | 269.32 |
4 | Diabetes | Diarrhea | 93 | f | 4.14 | N.D. | No 2 | 31.1 | 13.8 | 69 | F | Metronidazole | ||
5 | Kidney disease with dialysis and diabetes | Abdominal pain, nausea, and fever | 78 | m | 12.5 | 4.48 | Yes | 24.3 | 8.1 | 349 | R | None | 254.5 | 259 |
6 | Hirschsprung’s disease | Obstipation and vomiting | 1 | m | 4.01 | <1 | Yes | 27.7 | 14.3 | 20 | N | None | 47 | 47.15 |
7 | Alcoholism | Diarrhea for one week and cachexia | 69 | f | 3.63 | 11.67 | Yes | 20.9 | 5.6 | 60 | F | Vancomycin (t.n.a. 6) | 182.33 | 193.98 |
8 | Rheumatoid arthritis and chronic renal failure | Diarrhea for one week and exsiccosis | 94 | m | 15.3 | 2.93 | Yes | 21.9 | 24.1 | 184 | R | Vancomycin (19.17) | 331.25 | 334.17 |
9 | Rectal carcinoma and chronic renal failure | Ileus, abdominal pain, and weight loss | 83 | m | 13.75 | 4.1 | Yes | 31.7 | 15.4 | 106 | N | Metronidazole (15.5) | 0 7 | 280.25 |
10 | Ulcerative colitis and chronic renal failure | Diarrhea and fever | 90 | f | 12.75 | 5.87 | Yes | 23.5 | 11.3 | 110 | R | Vancomycin, metronidazole (9.5) | 204 | 209.82 |
11 | Granulomatosis, monoclonal gammopathy, diabetes, dementia, UTI 4, and sepsis | Diarrhea and fever | 85 | f | 18 | 6.84 | Yes | 36.8 | 22.7 | 285 | F | Vancomycin (t.n.a. 6) and piperacillin–tazobactam (2) | 215.5 | 577.23 |
12 | CHD 5, asthma, and osteosynthesis after femur fracture | Diarrhea for more than one week | 85 | f | 19.6 | 5.22 | Yes | 28.3 | 15.1 | 132 | F | Vancomycin (t.n.a. 6) | 143 | 148.25 |
13 | Chronic venous insufficiency, recurrent UTI 4, and abscessed symphysis | Diarrhea, exsiccosis, and fever | 80 | m | 8.1 | 3.85 | Yes | 23.3 | 31 | 63 | F | Vancomycin (t.n.a 6) | 114.5 | 129.78 |
14 | Stroke condition, adipositas, sepsis | Diarrhea and fever | 75 | f | 22.6 | 4.25 | Yes 8 | 22.2 | 21.9 | 80 | F | Vancomycin. Metronidazole (t.n.a. 6) and piperacillin–tazobactam (0.7) | t.n.a. 6 | t.n.a. 6 |
15 | Malignant melanoma | Diarrhea and fever | 46 | m | 12.43 | 2.75 | Yes | 26.3 | 4.9 | 39 | F | Vancomycin and ampicillin–sulbactam (13.23) | 417 | 420.03 |
16 | Hirschsprung’s disease | Diarrhea and fever | <1 | f | 13.6 | <1 | Yes | 23.2 | 18.4 | N.D. | F | Metronidazole (14) | 137.88 | 137.88 |
17 | Pancreatic carcinoma | Diarrhea, exsiccosis, and abdominal pain | 59 | m | 5.38 | 10.37 | Yes | 31.6 | 15 | 60 | F | Vancomycin (15.25) | 125.25 | 135.67 |
18 | Alzheimer’s disease, CHD 5, diabetes, and chronic renal failure | Diarrhea | 83 | f | 3.07 | 8.17 | Yes | 26 | 4.7 | 168 | F | Vancomycin and metronidazole (6.1) | 151.5 | 159.6 |
19 | Hodgkin‘s disease, conditions after CDI, and sepsis | Diarrhea and vomiting | 60 | m | 5.08 | 8.97 | Yes | 28.4 | 21.4 | 103 | R | Vancomycin (8.75) and meropenem (4.75) | 188.5 | 197.52 |
20 | Short bowel syndrome, ileostomy | Abdominal pain, fever | 12 | m | 5.5 | 4 | No 9 | 29.4 | 6 | 41 | N | None |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Iffland, A.; Zechel, M.; Lewejohann, J.-C.; Edel, B.; Hagel, S.; Hartmann, M.; Löffler, B.; Rödel, J. Experience with PCR Testing for Enteric Bacteria and Viruses of Emergency Department Patients with Acute Gastroenteritis: Are There Implications for the Early Treatment of Clostridioides difficile Infection? Antibiotics 2024, 13, 243. https://doi.org/10.3390/antibiotics13030243
Iffland A, Zechel M, Lewejohann J-C, Edel B, Hagel S, Hartmann M, Löffler B, Rödel J. Experience with PCR Testing for Enteric Bacteria and Viruses of Emergency Department Patients with Acute Gastroenteritis: Are There Implications for the Early Treatment of Clostridioides difficile Infection? Antibiotics. 2024; 13(3):243. https://doi.org/10.3390/antibiotics13030243
Chicago/Turabian StyleIffland, Andreas, Maria Zechel, Jan-Christoph Lewejohann, Birgit Edel, Stefan Hagel, Michael Hartmann, Bettina Löffler, and Jürgen Rödel. 2024. "Experience with PCR Testing for Enteric Bacteria and Viruses of Emergency Department Patients with Acute Gastroenteritis: Are There Implications for the Early Treatment of Clostridioides difficile Infection?" Antibiotics 13, no. 3: 243. https://doi.org/10.3390/antibiotics13030243
APA StyleIffland, A., Zechel, M., Lewejohann, J. -C., Edel, B., Hagel, S., Hartmann, M., Löffler, B., & Rödel, J. (2024). Experience with PCR Testing for Enteric Bacteria and Viruses of Emergency Department Patients with Acute Gastroenteritis: Are There Implications for the Early Treatment of Clostridioides difficile Infection? Antibiotics, 13(3), 243. https://doi.org/10.3390/antibiotics13030243